Spirit Scientific biotech, leader in regenerative medicine, made its debut at BIO Asia-Taiwan 2025.
The company showcased its core BMLT®, which transforms biomaterials into stable, quantifiable, and lyophilized forms.
This technology’s key application is in enhancing traditional PRP (platelet-rich plasma) therapy.
By preparing a precise, consistent Platelet Lyophilized Treatment(PLT) product, Spirit Scientific biotech eliminates the variability of standard PRP injections.
With over 36,000 cases and partnerships with more than 1,300 medical institutions, the company is now seeking new collaborations to expand its technology’s applications. Spirit Scientific biotech has also established a subsidiary in Japan, demonstrating its commitment to showcasing Taiwan’s medical expertise on the global stage.
Source: https://news.gbimonthly.com/tw/article/show.php?num=78890
